NCT03352947View on ClinicalTrials.gov

Continuous vs Intermittent Dabrafenib Plus Trametinib in BRAFV600 Mutant Stage 3 Unresectable or Metastatic Melanoma

PHASE2CompletedINTERVENTIONAL
Enrollment

79

Participants

Timeline

Start Date

November 3, 2017

Primary Completion Date

March 31, 2020

Study Completion Date

November 27, 2020

Conditions
Melanoma
Interventions
DRUG

Dabrafenib

150mg Dabrafenib twice daily day 1-21 of 28 day cycle in intermittent arm Day 1-28 of 28 day cycle in continuous arm

DRUG

Trametinib

Trametinib 2mg once daily Day 1-14 of a 28 day cycle in intermittent arm Day 1-28 of a 28 day cycle in the continuous arm

Trial Locations (1)

CB2 2QQ

Addenbrooke's Hospital, Cambridge

All Listed Sponsors
collaborator

National Institute for Health Research, United Kingdom

OTHER_GOV

collaborator

Oxford University Hospitals NHS Trust

OTHER

collaborator

University of Oxford

OTHER

lead

Cambridge University Hospitals NHS Foundation Trust

OTHER

NCT03352947 - Continuous vs Intermittent Dabrafenib Plus Trametinib in BRAFV600 Mutant Stage 3 Unresectable or Metastatic Melanoma | Biotech Hunter | Biotech Hunter